Spruce Biosciences Inc
NASDAQ:SPRB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7
2 390.625
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Spruce Biosciences Inc
Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Daly City, California and currently employs 15 full-time employees. The company went IPO on 2020-10-09. The firm is focused on developing and commercializing therapies for rare endocrine disorders. The firm's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a potent and selective, non-steroidal, oral, small-molecule antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is a regulator of the production of adrenocorticotropic hormone (ACTH). Its CAHmelia-203, is a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with CAH with poor disease control. Its CAHmelia-204, is a second Phase IIb clinical trial in adult patients with CAH with good disease control focused on glucocorticoid reduction. The company has also conducted two Phase IIa clinical trials of tildacerfont in adult patients with CAH on stable glucocorticoid therapy.
Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Daly City, California and currently employs 15 full-time employees. The company went IPO on 2020-10-09. The firm is focused on developing and commercializing therapies for rare endocrine disorders. The firm's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a potent and selective, non-steroidal, oral, small-molecule antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is a regulator of the production of adrenocorticotropic hormone (ACTH). Its CAHmelia-203, is a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with CAH with poor disease control. Its CAHmelia-204, is a second Phase IIb clinical trial in adult patients with CAH with good disease control focused on glucocorticoid reduction. The company has also conducted two Phase IIa clinical trials of tildacerfont in adult patients with CAH on stable glucocorticoid therapy.
